BGB-B3227

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameBGB-B3227
Drug Alias NameBGB-B3227
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-MUC1Anti-Low affinity immunoglobulin gamma Fc region receptor III-A
TargetsMucin-1Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeOne Medicines (Beijing) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdBeOne Medicines (Beijing) Co Ltd
Inactive CompaniesBeOne Medicines Ltd
Active IndicationsNeoplasm MetastasisLung NeoplasmsGastrointestinal Neoplasms
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A